Andrew Huberman· PhD
What's cool about that is that they kind of found two things, right? They found this one stimulation protocol that does have some antidepressant effect. It's limited, it doesn't treat everybody, it does have some antidepressant effect. And this bigger concept that a neuromodulation device is kind of like a pharmaceutical company for you, right? That in a given individual, a TMS device or whatever neuromodulation device is able to generate, you can create a stimulation approach that is specific to a given condition and specific to an individual. And so the physical layer is just how you exert that, similarly to how we make pharmaceutical drugs in a pharmaceutical company. But the actual therapy itself is what you do, where you do it. And so what we learned from, you know, another 20, 30 years of this is that you can modify the stimulation protocol in such a way where you can create a whole new treatment and put it through the same TMS device or, thank god, an evolved version of it where you don't have to dunk it in ice baths and they can actually really handle much more aggressive stimulation approaches.